Inogen Inc Stock Analysis
| INGN Stock | USD 7.19 0.08 1.13% |
At the current market price of $7.19, INGN trades below the analyst target price of $12.67. This stock analysis positions INGN relative to a fundamental value benchmark derived from reported financials. With profitability currently negative, the analytical focus for INGN centers on cost structure and the path to margin recovery.
INGN holds a debt-to-equity ratio of 0.07 relative to health care peers. According to the filing dated December 31, 2025, Net Debt To EBITDA is holding steady around 31.71x, while Net Debt is staying broadly flat near $-86.25 million, indicating that Inogen holds more cash than total debt and operates with a net cash position. Inogen's leverage relative to sector peers provides context — the same debt ratio carries different implications across industries. Earnings before interest and taxes (EBIT) relative to interest expense measures the margin of safety on debt service. Asset vs Debt
Equity vs Debt
Price Book 0.99 | Price Sales 0.56 | Shares Float 24.02 million | Wall Street Target Price 12.67 | Earnings Share -0.86 |
Inogen Inc reported $348.7 million in Total Revenue, a net loss of $22.7 million, and $2.1 million in Non Operating Income Net Other.
Inogen |
Stock Analysis Notes
About 77.0% of INGN shares are owned by institutional investors. INGN has price-to-book (P/B) ratio of 0.99. Equities trading below book value may carry value potential, though margin and return quality should confirm. Inogen reported a loss per share of 0.86. INGN had not issued any dividends in recent years. Inogen Inc reported $0.15 in Intangibles To Total Assets, $298.6 million in Total Assets, and a Return On Assets of -7.2%.Retained Earnings | $-166.8 million |
Investor Insights and Alerts
| INGN reported previous year's revenue of $348.67 million. Net Loss for the year was -$22.75 million with profit before overhead, payroll, taxes, and interest of $154.26 million. | |
| Inogen Inc currently holds about $223.62 million in cash as of latest reporting with -$11.22 million of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.78, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from MacroaxisInsider: Disposition of 594 shares by James Rodberg of Sight Sciences at 7.48 subject to Rule 16 b-3 |
Largest EPS Surprises
EPS surprise history helps explain abrupt moves in Inogen's price behavior. A negative gap to consensus tends to pressure valuation, while a positive gap can support re-rating. For this stock, read EPS surprises with profitability quality and forward revisions.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2014-05-13 | 2014-03-31 | 0.04 | 0.05 | 0.01 | 25 | ||
2014-03-27 | 2013-12-31 | 0.02 | 0.01 | -0.01 | 50 | ||
2021-02-24 | 2020-12-31 | -0.26 | -0.23 | 0.03 | 11 |
Environmental, Social, and Governance (ESG) Scores
Reviewing Inogen's ESG trend shows whether governance quality and stakeholder risk are improving or declining. For Inogen Inc, ESG considerations carry the most weight in governance discipline and workforce stability — areas where operational risk intersects with stakeholder outcomes.
Thematic Classifications
Themes linked to Inogen Inc are useful because they connect a single stock to a larger investable concept that can be researched and optimized as a group. The practical benefit is that this enables optimization around a trend, not just around one name that may or may not remain the best expression of that trend.
 | Obamacare RepealLarge healthcare related equities associated with Obamacare | |
 | Baby Boomer ProspectsMega stocks, funds and ETFs that tend to appeal to people considering retirement from the work force | |
 | Trump EquitiesCompanies that have responded positively to Trump presidency |
Top Institutional Investors Holding Inogen Stock
At micro-cap scale, institutional coverage and secondary-market liquidity are typically well established. At Inogen Inc's scale, fund flows and index rebalancing drive most of the daily volume. The business currently sits in the Health Care sector and the Health Care Equipment & Services industry. That institutional share is enough to anchor governance but can also amplify selling when risk sentiment shifts.
| Shares | State Street Corp | 2025-12-31 | 511.8 K | Federated Hermes Inc | 2025-12-31 | 485.4 K | Jpmorgan Chase & Co | 2025-12-31 | 469.3 K | Prudential Financial Inc | 2025-12-31 | 458.1 K | Csm Advisors, Llc | 2025-12-31 | 416 K | Nuveen, Llc | 2025-12-31 | 413.5 K | Jacobs Levy Equity Management, Inc. | 2025-12-31 | 285 K | Qube Research & Technologies | 2025-12-31 | 262.9 K | Citadel Advisors Llc | 2025-12-31 | 242.3 K | Blackrock Inc | 2025-12-31 | 1.7 M | Vanguard Group Inc | 2025-12-31 | 1.4 M |
Market Capitalization
At roughly $194.28 million, Inogen Inc belongs to the small-cap segment of health care equipment & supplies companies. The current market cap profile is reinforced by enterprise value near $88.35 million, a workforce of about 753 people, and about 27.32 million shares outstanding.Profitability
A profitability review of Inogen Inc connects sales quality and cost control with the ability to produce steady returns across market cycles. The key question is whether current profitability is lasting, cyclical, or boosted by items that may not repeat. INGN has Profit Margin (PM) of -7.0%. Similarly, it shows Operating Margin (OM) of -12.0%.| Last Reported | End Of Year Estimate | ||
| Return On Tangible Assets | -0.09 | -0.08 | |
| Return On Capital Employed | -0.13 | -0.12 | |
| Return On Assets | -8.00% | -7.00% | |
| Return On Equity | -12.00% | -11.00% |
Management Efficiency
INGN has return on total asset (ROA) of -6.35% indicating the asset base is not generating profit. Negative, indicating a net loss relative to revenue. Inogen also reports a return on stockholder's equity (ROE) of -12.43%, which implies that it generated no returns to current stockholders.| Last Reported | End Of Year Estimate | ||
| Book Value Per Share | 7.07 | 7.37 | |
| Tangible Book Value Per Share | 5.55 | 6.23 | |
| Price Book Value Ratio | 0.95x | 0.9x | |
| Enterprise Value Multiple | -35.43x | -33.66x | |
| Price Fair Value | 0.95x | 0.9x | |
| Enterprise Value | $96.37 million | $91.56 million |
Management quality at Inogen Inc matters because strategic decisions eventually show up in margins, cash conversion, capital allocation, and the market's willingness to assign a premium multiple. This analysis evaluates whether leadership is improving the economics of the business in ways that can persist once the operating environment deteriorates.
Operating Margin | Three Month Return 27.03 | Short Long Term Debt Total | Ten Year Return -85.33 | Three Year Return -39.32 |
Technical Drivers
Market data as of the 8th of May shows Inogen priced at 7.19 per share. Measured indicators report Risk Adjusted Performance of 0.1189, downside deviation of 2.62, and Market Risk Adjusted Performance of 0.3414. The model examines historical data series to identify measurable trend characteristics. Technical levels are measured against peer distributions.Price Movement Analysis - Bollinger Bands
This analysis covers thirty-eight data points across the selected time horizon. Bollinger Bands frame Inogen price range using a moving average and volatility bands. Movement toward the lower band may indicate short-term downside pressure, while approaches to the upper band can reflect resistance levels or momentum continuation.
Insider Trading Activities
Reviewing insider trades in Inogen Inc shows whether management is acting in line with the public story on growth and strategy. The goal is to tell routine pay-related sales apart from trades that reflect genuine conviction.
Outstanding Bonds
Inogen Inc may use bonds as part of its capital structure to fund operations, refinance liabilities, or support acquisitions and other long-duration investments. Used together with earnings and cash-flow analysis, the bond stack can reveal whether leverage is a manageable tool or a developing constraint.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley Jul Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Predictive Daily Indicators
For active positions in Inogen Inc, intraday data shows when a move is gaining strength and when it is fading. For most traders, the benefit is faster feedback on momentum, which sharpens both entries and exits.
Corporate Filings
8K | 7th of May 2026 Report filed with the SEC to announce major events that shareholders should know about | |
| 4th of May 2026 Other Reports | ||
| 28th of April 2026 Other Reports | ||
| 17th of April 2026 Other Reports | ||
F3 | 8th of April 2026 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | |
8K | 6th of April 2026 Report filed with the SEC to announce major events that shareholders should know about | |
8K | 30th of March 2026 Report filed with the SEC to announce major events that shareholders should know about | |
13A | 27th of March 2026 An amended filing to the original Schedule 13G |
Forecast Models
Forecast models for Inogen Inc use past prices and returns to estimate how the stock may behave under similar conditions. They work best when compared with volatility and catalyst risk rather than treated as a single price target.Financial Strength and Earnings Quality Indicators
Inogen Inc financial ratings play a critical role in determining how much Inogen has to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Inogen's borrowing costs.| Piotroski F Score | 6 | Healthy | View |
| Beneish M Score | -3.08 | Unlikely Manipulator | View |
Debt to Cash Allocation
The debt-to-cash mix for Inogen helps explain how management balances flexibility and funding cost through a business cycle.
Total debt stands at approximately $17.48 million with Debt to Equity (D/E) ratio of 0.07. Inogen has a current ratio of 5.21, suggesting that it is liquid enough and is able to pay its financial obligations when due. Inogen's use of debt should be considered alongside its cash position and equity base.Total Assets Over Time
Assets Financed by Debt
Debt finances 9.74% of INGN's total assets — a relatively low share of the asset base, though leverage can still appear elevated relative to peers when measured against equity rather than total assets.Inogen Debt Ratio | 9.74 |
Corporate Bonds Issued
Inogen Short Long Term Debt Total
Short Long Term Debt Total | $14.27 million |
Stock Analysis Methodology
As a micro-cap equity, Inogen is scored on valuation, solvency, and operating efficiency. Inogen operates in Health Care Equipment & Supplies within Health Care Equipment & Services in Health Care. Financial distress probability is estimated at 5%, indicating low near-term solvency risk. Inogen trades at P/E of 61.63, P/B of 0.99.
Inogen Inc figures are aggregated from periodic company reporting and market reference feeds and normalized across reporting formats.
Editorial review and methodology oversight provided by: Rifka Kats, Member of Macroaxis Editorial Board
Current Inogen Analyst Rating Consensus
| Target Price | Consensus | # of Analysts | |
| 12.67 | Buy | 3 | Odds |
The analyst consensus for Inogen Inc is compiled from recommendations across research providers. The consensus average reflects the central tendency of analyst ratings for Inogen. Wall Street analysts covering Inogen Inc typically update price targets and ratings quarterly. A rising consensus or cluster of upgrades for Inogen often signals improving fundamental momentum.
Inogen Stock Analysis Indicators
Diagnostics snapshot includes 23 indicators such as Begin Period Cash Flow, Total Stockholder Equity, Capital Lease Obligations.
| Begin Period Cash Flow | 117.42 million | |
| Total Stockholder Equity | 192.23 million | |
| Capital Lease Obligations | 17.48 million | |
| Property Plant And Equipment Net | 52.86 million | |
| Cash And Short Term Investments | 119.58 million | |
| Cash | 103.73 million | |
| 50 Day M A | 6.515 | |
| Net Interest Income | 4.38 million | |
| Total Current Liabilities | 63.53 million | |
| Investments | -15.83 million | |
| Stock Based Compensation | 8.01 million | |
| Common Stock Shares Outstanding | 27.18 million | |
| Total Cashflows From Investing Activities | -26.21 million | |
| Tax Provision | -632,000 | |
| Quarterly Earnings Growth Y O Y | 0.873 | |
| Free Cash Flow | -21.6 million | |
| Other Current Assets | 13.89 million | |
| Accounts Payable | 29.44 million | |
| Net Debt | -86.25 million | |
| Other Operating Expenses | 378.88 million | |
| Non Current Assets Total | 100.33 million | |
| Liabilities And Stockholders Equity | 298.62 million | |
| Non Currrent Assets Other | 6 million |